Illustrative image.

Promacta

Name: Promacta
Brand: Novartis
Availability: InStock

Eltrombopag

Prescription required

$4785.00

25mg · 3 × 28 tablets · 3 months supply

BrandBranded medicine· By Novartis

$1595.00 per month

Strength

How long a supply?

1 month$1595.00 a monthOne-off$1595.00

3 months$1595.00 a monthOne-off$4785.00

6 months$1595.00 a monthOne-off$9570.00

Supplied from Israel

Test mode: no payment is taken. View cart

Annual cost

$20735a year at this pack size

Prescription required

Upload your prescription after ordering, or send it to our pharmacy team. We dispense only against a valid prescription.

25mg

50MG

FDA boxed warningRisk for hepatic decompensation in patients with chronic hepatitis c and risk of hepatotoxicity

In patients with chronic hepatitis C, PROMACTA in combination with interferon and ribavirin may increase the risk of hepatic decompensation.

PROMACTA may increase the risk of severe and potentially life-threatening hepatotoxicity. Monitor hepatic function and discontinue dosing as recommended.

Warnings and Precautions, Laboratory Test Interference

6/2025

Read this with the rest of the clinical information

About Promacta

Overview

Promacta (eltrombopag) is a prescription tablet used to treat low platelet counts in adults and children aged 1 year and older with persistent or chronic immune thrombocytopenia (ITP), when corticosteroids, immunoglobulins or spleen removal have not worked well enough and the condition increases bleeding risk. It is also used for low platelet counts in people with chronic hepatitis C when these prevent starting or continuing interferon-based treatment. For severe aplastic anemia, it is used with standard immune-suppressing treatment as initial therapy in adults and children aged 2 years and older, or in patients who have not responded sufficiently to immune-suppressing treatment. It works by activating thrombopoietin receptors, which stimulate the development of platelet-producing cells and increase platelet production.

What it treats

- Low platelet counts in adults and children aged 1 year and older with persistent or chronic immune thrombocytopenia (ITP), when corticosteroids, immunoglobulins or spleen removal have not worked well enough and the low platelet count and clinical condition increase bleeding risk. - Low platelet counts in people with chronic hepatitis C when these prevent starting or limit continuing interferon-based treatment. - Severe aplastic anemia in adults and children aged 2 years and older, as first-line treatment together with standard immunosuppressive therapy. - Severe aplastic anemia that has not responded well enough to immunosuppressive therapy.

Safety information

Side effects

Common side effects include anemia (low red blood cell count), nausea, fever, increased levels of the liver enzyme ALT, cough, tiredness, headache and diarrhea. Serious risks to discuss promptly with a doctor include liver damage, worsening liver function in people with chronic hepatitis C, blood clots and cataracts. Blood clots in the portal vein, which carries blood to the liver, have been reported in people with chronic liver disease taking Promacta. In people with myelodysplastic syndromes, there is an increased risk of death and progression to acute myeloid leukemia. Liver function must be checked before and during treatment, and platelet counts must be monitored regularly.

FDA boxed warning

Risk for hepatic decompensation in patients with chronic hepatitis c and risk of hepatotoxicity

In patients with chronic hepatitis C, PROMACTA in combination with interferon and ribavirin may increase the risk of hepatic decompensation.

PROMACTA may increase the risk of severe and potentially life-threatening hepatotoxicity. Monitor hepatic function and discontinue dosing as recommended.

Warnings and Precautions, Laboratory Test Interference

6/2025

A boxed warning is the strongest warning the US Food and Drug Administration requires on a medicine label. Text is taken from the official label, with internal section references removed.

Before taking this medicine

The label lists no formal contraindications for Promacta. However, important cautions apply: Promacta can cause liver toxicity. Liver function should be checked before and during treatment. Blood clots in the portal vein have been reported in people with chronic liver disease taking Promacta. Platelet counts should be monitored regularly. The label warns of an increased risk of death and progression to acute myeloid leukemia in people with myelodysplastic syndromes. Women should not breastfeed during treatment.

Using Promacta

Dosing

Dosing is set by your prescriber. Each health care professional may prescribe medication differently according to a patient's medical history and condition, so follow the directions on your prescription label and speak to your doctor or pharmacist before changing anything.

Storage

Store below 25°C in a dry place, in the original pack, away from direct light and moisture. Do not keep it in a bathroom. Keep all medicines out of the sight and reach of children.

Clinical information on this page is summarised from the US FDA label PROMACTA (ELTROMBOPAG OLAMINE) TABLET, FILM COATED PROMACTA (ELTROMBOPAG OLAMINE) POWDER, FOR SUSPENSION [NOVARTIS PHARMACEUTICALS CORPORATION] (DailyMed, retrieved 19 September 2026).

Reviews

No reviews yet. Mail Order Drugs opened recently, and we publish reviews only from verified customers of this site, so this space stays empty until real ones arrive.